November is Pancreatic Cancer Awareness Month. At A2 Bio, we're committed to advancing innovative oncology treatments leveraging our logic-gated Tmod? CAR T-cell therapy. A2 Bio has two current clinical studies, EVEREST-1 (NCT05736731) and EVEREST-2 (NCT06051695), that are actively enrolling patients with pancreatic cancer, as well as other solid tumors. Our company and staff are dedicated to making a meaningful impact for those affected by this devastating illness. To read more about the EVEREST-1 and EVEREST-2 studies, please visit: https://lnkd.in/ge7KqZ8T #PancreaticCancerAwareness #SupportPancreaticCancer #HopeForACure #CellTherapy #A2Bio
A2 Biotherapeutics, Inc.
生物技术研究
Agoura Hills，CA 13,615 位关注者
Powerful & precise T cell therapy that attacks solid tumors while sparing normal cells.
关于我们
A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors. A2 engineers T cells that target the loss of genetic material in tumors, enabling the selective killing of tumor cells while leaving normal cells unharmed. The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang and has raised $136M since inception. Our investors include The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents) and Hartford HealthCare Endowment.
- 网站
-
https://www.a2bio.com
A2 Biotherapeutics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Agoura Hills，CA
- 类型
- 私人持股
- 创立
- 2018
- 领域
- Biotechnology、Immunotherapy、Oncology、Research、Target Identification、Cell Therapy、Manufacturing和Drug Development
地点
-
主要
获取路线
30301 Agoura Road
Suite 210
US，CA，Agoura Hills，91301
A2 Biotherapeutics, Inc.员工
动态
-
A2 Biotherapeutics is proud to be a 2025 BioSpace "Best Places to Work" Winner! This year, A2 ranked #5 among BioSpace's top 30 small employers. We are incredibly proud that our dedication to finding a radical new way to treat solid tumors, our talented professionals, and the progress we are making as a clinical stage cell therapy company are being recognized across the industry. For more information on the BioSpace 2025 Best Places to Work in Life Sciences winners, please review the recent BioSpace announcement: https://lnkd.in/eVW6vt-2 For more information about A2 Bio, please visit: https://www.a2bio.com/ #A2Bio #biospace #celltherapy #BASECAMP-1 #EVEREST-1 #EVEREST-2
-
-
A2 Biotherapeutics is proud to be a 2025 BioSpace "Best Places to Work" Winner! This year, A2 ranked #5 among BioSpace's top 30 small employers. We are incredibly proud that our dedication to finding a radical new way to treat solid tumors, our talented professionals, and the progress we are making as a clinical stage cell therapy company are being recognized across the industry. For more information on the BioSpace 2025 Best Places to Work in Life Sciences winners, please review the recent BioSpace announcement: https://lnkd.in/eVW6vt-2 For more information about A2 Bio, please visit: https://www.a2bio.com/ #A2Bio #biospace #celltherapy #BASECAMP-1 #EVEREST-1 #EVEREST-2
-
-
A2 Bio recently closed out a successful conference at the Society for Immunotherapy of Cancer (SITC) 2024 in Houston, Texas. Dr. Julian Molina, M.D., Ph.D. from Mayo Clinic, Rochester, MN, presented an oral presentation on the BASECAMP-1 prescreening study highlighting an innovative approach to overcome the operational burden of finding diverse participants for precision medicine studies. A2 Bio presented 5 posters with updates on early safety and biomarker data from the ongoing EVEREST-1 (NCT05736731) clinical study and enrollment updates for the EVEREST-2 (NCT06051695) clinical study. A2 Bio thanks the participants and clinical site teams for their support and partnership. Looking forward to the SITC 2025 meeting in National Harbor, Maryland! For more information on A2 Bio's press release, please visit: https://lnkd.in/gj5XFe7c For more information on our clinical studies, please visit: https://lnkd.in/ge7KqZ8T #SITC #SITC2024 #A2Bio #Tmod #CellTherapy
-
-
A2 Bio shared progress of its Tmod? CAR T-cell clinical programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). In an oral presentation today, A2 Bio shared progress in increasing diversity of participants enrolled in the BASECAMP-1 (NCT04981119) nationwide prescreening study for all Tmod? CAR T-cell trials. The company also presented posters highlighting early safety and biomarker data from the ongoing EVEREST-1 trial (NCT05736731), enrollment updates for the EVEREST-2 trial (NCT06051695), and updates on adaptations to boost potency and preserve selectivity of its Tmod? -based precision cell therapies. For more information on A2 Bio's press release, please visit: https://lnkd.in/gj5XFe7c For more information on our clinical studies, please visit: https://lnkd.in/ge7KqZ8T #SITC #SITC2024 #A2Bio #Tmod #CellTherapy
-
-
The A2 Bio Volunteer Club recently participated in the L.A. Cancer Challenge (LACC) at UCLA. Our team, led by Will Go, MD, PhD, Chief Medical Officer, received a Gold Medal for raising over $2,500! The LACC, organized by the Agi Hirshberg Foundation (pictured with Drs. Donahue, Wainberg and Go), raised over $600,000 to fund cancer research and programs designed to improve patient care, offer better treatment options, and ultimately find a cure for pancreatic cancer. Special thanks to the A2 Bio staff who participated in the event and contributed to support the Agi Hirshberg Foundation. To learn more about A2 Bio's clinical studies, please visit: https://lnkd.in/ge7KqZ8T #A2Bio #run4cure #run2endpc #LACancerChallenge
-
-
Happy Halloween! A2 Bio recently hosted a Halloween kids parade and potluck party at our offices in Agoura Hills, CA. Team members dressed up and participated in a costume contest. Teamwork is a core value at A2 Bio, and it was on full display yesterday. To learn more about our company and team, please visit: https://www.a2bio.com/ #A2Bio #Teamwork #Halloween #CellTherapy
-
-
A2 Bio is honored to receive the MasterControl Innovation Excellence Award, accepted by QA Specialist Dan Lombardo. The award recognizes our groundbreaking Tmod? cell therapy platform which uses logic-gating to distinguish between tumor and normal cells - a significant advancement in cancer treatment. We thank the MasterControl team for this recognition and continued partnership as we advance our innovative cell therapies. For more information, please review the MasterControl Quality Awards webpage: https://lnkd.in/gxnZTfry #A2Bio #MCMastersSummit #MastersOfExcellence #InnovationExcellence #Tmod #CellTherapy
-
-
A2 Biotherapeutics, Inc announced the acceptance of six abstracts for presentation at the Society for Immunotherapy of Cancer (SITC) annual meeting on November 8-10, 2024 in Houston. We are especially proud to present safety and biomarker data on the EVEREST-1 (NCT05736731) study as well as an oral presentation highlighting continued progress in enhancing the diversity of patients enrolled in the BASECAMP-1 prescreening trial. A2 Bio will also present progress on our EVEREST-2 trial (NCT06051695), and adaptations to boost potency and preserve selectivity of Tmod? based cell therapies. For more information on our press release, please visit: https://lnkd.in/gvnFeWsK For more information on our clinical studies, please visit: https://lnkd.in/ge7KqZ8T #SITC #SITC2024 #A2Bio #Tmod #CellTherapy
-
-
As September, Ovarian Cancer Awareness Month, comes to a close, it's important to reflect on the work being done to address this challenging disease. At A2 Bio, we're committed to advancing innovative treatments. We are currently testing A2B694 in the EVEREST-2 study (NCT06051695), a potential treatment for ovarian cancer in patients whose tumors express MSLN and have lost HLA-A*02. Our goal is to make a meaningful impact for those affected by this devastating illness. To read more about the EVEREST-2 study, please visit: https://lnkd.in/gmbGrGjP #OvarianCancerAwareness #CellTherapy #A2Bio
-